Sildenafil-associated consecutive nonarteritic anterior ischaemic optic neuropathy, cilioretinal artery occlusion, and central retinal vein occlusion in a haemodialysis patient

Gedik, Şansal; Yılmaz, Gürsel; Akova, Yonca A.

doi:10.1038/sj.eye.6702445

Cited by 30 publications

(26 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[7][8][9][10][11][12][13] However, thesehavebeeninfrequentandofunclearcausebecausemany men who use PDE5 inhibitors have comorbid diseases that predispose them to these visual complications.…”

mentioning

confidence: 98%

Retinal Effects of 6 Months of Daily Use of Tadalafil or Sildenafil

Cordell¹,

Maturi²,

Costigan³

et al. 2009

Arch Ophthalmol

View full text Add to dashboard Cite

mentioning

confidence: 98%

Retinal Effects of 6 Months of Daily Use of Tadalafil or Sildenafil

Cordell¹,

Maturi²,

Costigan³

et al. 2009

Arch Ophthalmol

View full text Add to dashboard Cite

“…Ischemic optic neuropathy was reported in five cases. It involved one eye in three cases [38,39,41] and both eyes in two [40,43]. Hsien‐wen et al.…”

Section: Resultsmentioning

confidence: 99%

Are Phosphodiesterase Type 5 Inhibitors Associated with Vision-Threatening Adverse Events? A Critical Analysis and Review of the Literature

Azzouni

Samra

2011

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Introduction Phosphodiesterase type 5 (PDE5) inhibitors are the first line drugs for treatment of erectile dysfunction. Sildenafil (ViagraR), tadalafil (CialisR), and vardenafil (LevitraR) are from the same class of drugs that inhibit PDE5. Transient visual symptoms such as change in color perception and increased light sensitivity are well-known adverse effects of these drugs and occur in 3–11% of sildenafil users. Vision-threatening (serious) ocular complications, such as nonarteritic ischemic optic neuropathy and cilio-retinal artery occlusion have rarely been reported in PDE5 inhibitor users. Aims To highlight and analyze the most recently published case literature on serious ocular complications of PDE5 inhibitors. Methods Search of the peer-reviewed English literature was conducted using Medline. The following databases also were searched: Cumulative Index to Nursing and Allied Health Literature, Cochrane Library, Global Health, and MD Consult. The causality assessment of the reported adverse drug reactions was analyzed by applying both the World Health Organization (WHO) Probability Scale and the criteria utilized by the National Registry of Drug-Induced Ocular Side Effects. Main Outcome Measures To scientifically and objectively find out if PDE5 inhibitors are associated with vision-threatening ocular complications. Results Eight case reports of serious PDE5 inhibitor-associated ocular complications were identified since January 2006 until February 2011. Case reports included cases of anterior and posterior nonarteritic ischemic optic neuropathy, central retinal vein occlusion, cilio-retinal artery occlusion, acute angle closure glaucoma and optic atrophy after sildenafil use. Conclusion There is lack of conclusive evidence to indicate a direct cause–effect relationship between PDE5 inhibitor use and vision-threatening ocular events. Men who use PDE5 inhibitors appear to suffer vision-threatening complications at the same frequency as the general population. However, minor visual adverse effects occur in 3–11% of users and they are transient and reversible.

show abstract

“…Furthermore, five cases have been reported in Canada [9]. There are 17 NAION case reports published in association with sildenafil and three in association with tadalafil (Tables 2-4) [7,20,[46][47][48][49][50][51][52][53][54][55]. A few of the cases associated with sildenafil and one case associated with tadalafil experienced temporary partial visual loss that became a fixed visual loss upon rechallenging.…”

Section: What Is Naion?mentioning

confidence: 97%

Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: Is there a link?

Hatzimouratidis

2007

Curr Urol Rep

View full text Add to dashboard Cite

Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy and one of the most common causes of sudden vision loss in the elderly. Recently, NAION has been associated with the use of phosphodiesterase type 5 inhibitors (PDE5i) in men with erectile dysfunction (ED). A causal relationship could not be established given the large number of men safely using PDE5i and the limited number of NAION cases reported in these men. ED and NAION share common risk factors; therefore, some men with ED should be expected to develop NAION. However, sudden vision loss or decreased vision in one or both eyes demands immediate cessation of PDE5i use and urgent patient assessment. No causal relationship between PDE5i and the development of NAION exists for the moment, yet physicians should be aware of a possible adverse reaction and inform patients accordingly.

show abstract

Sildenafil-associated consecutive nonarteritic anterior ischaemic optic neuropathy, cilioretinal artery occlusion, and central retinal vein occlusion in a haemodialysis patient

Cited by 30 publications

References 4 publications

Retinal Effects of 6 Months of Daily Use of Tadalafil or Sildenafil

Retinal Effects of 6 Months of Daily Use of Tadalafil or Sildenafil

Are Phosphodiesterase Type 5 Inhibitors Associated with Vision-Threatening Adverse Events? A Critical Analysis and Review of the Literature

Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: Is there a link?

Contact Info

Product

Resources

About